InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.046 -0.006 (-11.54%)+
Announcement
Release
19 Mar 2026 8:20AM
Price at Release
$0.052
Full Release
download
Summary
Immutep Limited has announced a positive update on its Phase I study of IMP761, a first-in-class LAG-3 agonist antibody targeted at autoimmune diseases. The study, which is a placebo-controlled, double-blind trial, showed that IMP761 was well tolerated across all dose levels with no safety concerns or dose-limiting toxicities observed. The initial phase, involving a single ascending dose, has been completed, and the study is now progressing into the multiple ascending dose phase. IMP761 is designed to modulate T-cell activity to restore immune tolerance, with potential applications in diseases like rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis. The Phase I results will be presented at the upcoming EULAR annual congress.
Key Points
  • Immutep has completed the single ascending dose portion of the IMP761 study.
  • IMP761 was well tolerated with no safety concerns at all dose levels.
  • The study is progressing into the multiple ascending dose phase.
  • IMP761 targets T-cell activity to restore immune tolerance.
  • Potential applications include rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.
  • The Phase I results will be presented at the EULAR annual congress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.